Right5 platform

We will launch the clinically validated drug dosing platform-environment Right5, which will help doctors and patients provide personalized dosing of drugs with innovative modern algorithms based on blood markers and phenotypes of the organism.

The new precision medicine dosing platform for the whole world, which consolidates the treatment procedure at the right moment, the right FIVE necessary components:
The right patient
The right drug
The right time
The right dose
The right route

Medications

The Right5 platform will initially consist of four products, one of which has been clinically validated and three of which are based on Therapeutic Drug Monitoring (TDM):

  • VANCOMYCIN – One of the most common intravenous antibiotics for Gram-positive microorganisms. The first line antibiotics for treatment of MRSA (methicillin resistant S.aureus) and MRSE (methicillin resistant S.epidermidis) worldwide.
  • HEPARIN (TDM) – Blood-thinning agent.
  • CYCLOSPORINE (TDM) – Immunosuppressive agent
  • VALPROIC ACID (TDM) – One of the most widely used anticonvulsant drug in the world, effective for most forms of epilepsy.
 

Key benefits of the platform – what is the advantage of using Right5 precision medicine dosing platform versus not using it?

  • Many drugs have a narrow therapeutic window, which means that there is very little difference between the dose that produces positive effects on the dose that is toxic. Thus, there is a risk of underdosing as well as toxic side effects. Side effects can be very serious form from time to time, such as kidney or liver failure, or loss of consciousness. Underdosing, in turn, is often associated with insufficient effect, i.e., that too low a dose of drug does not achieve the desired therapeutic result.
  • In addition to personal differences, there are a number of diseases that significantly affect the kinetics of drugs. For example, critical conditions, malignancies, organ failure. The pharmacokinetics of the drug, may also change during the same disease of a different patient.
  • Studies have shown that people differ from each other and that the concentrations of medicines vary from person to person after the same dose.
  • The determination of genes (pharmacogenetics) allows humans to be divided into fast or slow metabolisers but does not allow the determination of the appropriate personal dose. Today, there are often no other means of quantifying the effects of pharmacogenetic factors in a particular patient than assessing personal pharmacokinetics.
  • Determining the concentration of drugs (therapeutic drug monitoring) with consideration of the patient’s personal characteristics (Bayesian modeling) is the only option for operative individual / personal drug dosing.
  • From the above, we anticipate that in the near future, personal dosing for drugs with a narrow therapeutic window will become the usual approach / required norm, which will be / must be implemented by all medical institutions.